GPC3 and hepatocellular carcinoma: Several phase I studies are recruiting patients with advanced HCC and are employing CAR T-cells that target GPC3, which is highly expressed in LC and correlates with a poor prognosis (NCT04121273, NCT03198546, and NCT02905188) [50].